Tennessee (State or other jurisdiction of incorporation) |
001-15875 (Commission File Number) |
54-1684963 (I.R.S. Employer Identification No.) |
501 Fifth Street, Bristol, Tennessee (Address of principal executive offices) |
37620 (Zip Code) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
KING PHARMACEUTICALS, INC. |
||||
Date: November 6, 2008 | By: | /s/ Joseph Squicciarino | ||
Joseph Squicciarino | ||||
Chief Financial Officer |
2
Exhibit No. | Description | |
99.1
|
Press release of King Pharmaceuticals, Inc. dated November 6, 2008. |
3